Does masturbation cause hair loss? This is one of the most persistent myths in popular health culture, yet it has no credible scientific foundation. Hair loss is a common and often distressing condition affecting millions of people across the UK, with well-established clinical causes ranging from genetics and hormonal imbalances to nutritional deficiencies and certain medications. This article examines the evidence — or lack thereof — behind the masturbation–hair loss claim, explains the genuine mechanisms driving alopecia, and outlines when to seek medical advice and which evidence-based treatments are available through the NHS.

What Causes Hair Loss? Common and Clinically Recognised Factors

The most common cause of hair loss is androgenetic alopecia, driven by genetic predisposition and androgen activity. Other recognised causes include alopecia areata, telogen effluvium, thyroid disorders, nutritional deficiencies, certain medications, and scalp conditions.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss, known medically as alopecia, is an extremely common condition affecting millions of people across the UK. It can affect the scalp alone or the entire body, and may be temporary or permanent depending on the underlying cause. Understanding what genuinely drives hair loss is essential before exploring popular myths surrounding the condition.

The most clinically recognised causes of hair loss include:

• Androgenetic alopecia (male or female pattern baldness): The most prevalent form, driven by genetic predisposition and the influence of androgens on hair follicles.

• Alopecia areata: An autoimmune condition in which the immune system mistakenly attacks hair follicles, causing patchy hair loss.

• Telogen effluvium: A temporary shedding of hair triggered by physical or emotional stress, illness, hormonal changes (such as those following childbirth), or nutritional deficiencies.

• Thyroid disorders: Both hypothyroidism and hyperthyroidism can disrupt the normal hair growth cycle.

• Nutritional deficiencies: Low levels of iron or ferritin are well-recognised contributors to hair thinning. Associations with vitamin D and zinc have been reported, though the evidence is less consistent and routine testing is generally reserved for those with specific risk factors.

• Medications: Certain drugs — including chemotherapy agents, anticoagulants, retinoids, antithyroid drugs, and sodium valproate — list hair loss as a recognised side effect. A full medication review by a GP or pharmacist can help identify any contributory drugs.

• Scalp conditions: Fungal infections such as tinea capitis (particularly in children, where systemic antifungal treatment is required) or scarring conditions such as lichen planopilaris can permanently damage follicles and require prompt specialist referral.

• Traction alopecia: Hair loss caused by prolonged tension on the hair shaft from tight hairstyles.

• Trichotillomania: A compulsive urge to pull out one's own hair, which may benefit from psychological support.

Genetics remains the single most significant factor in pattern hair loss. According to NHS guidance, androgenetic alopecia accounts for the vast majority of hair loss cases in both men and women. Lifestyle factors such as smoking and poor nutrition may contribute to or exacerbate hair loss, particularly in predisposed individuals, and can also trigger telogen effluvium independently of genetic factors.

Scarring alopecias (such as lichen planopilaris and frontal fibrosing alopecia) are associated with permanent follicle destruction and should be referred promptly to a dermatologist, as early treatment may limit progression.

The Claimed Link Between Masturbation and Hair Loss Explained

Masturbation does not cause hair loss; this is a long-standing myth with no peer-reviewed evidence and is not recognised by any UK medical authority. Claims that ejaculation depletes protein or raises DHT to harmful levels are biologically implausible.

The idea that masturbation causes hair loss is a long-standing myth with no credible scientific basis. It has circulated in various forms for centuries, often rooted in historical moral attitudes towards sexual activity rather than any physiological evidence. No peer-reviewed clinical research supports a causal relationship between masturbation and hair loss, and UK authorities — including the NHS, NICE, and the MHRA — do not list masturbation as a cause of hair loss.

One of the most commonly cited theories is that ejaculation depletes the body of protein, which is then 'taken' from hair follicles. This is biologically implausible. Semen contains only trace amounts of protein — far too little to have any meaningful impact on the body's overall protein balance or hair growth cycle.

Another popular claim suggests that masturbation raises testosterone levels, which in turn increases dihydrotestosterone (DHT) — the hormone most directly linked to androgenetic alopecia. Whilst sexual arousal can cause transient, short-lived fluctuations in testosterone, these changes are minor and do not produce sustained hormonal shifts capable of accelerating hair loss. The body's hormonal regulation is tightly controlled, and brief spikes do not alter the long-term hormonal environment of hair follicles.

No evidence of a causal link between masturbation and hair loss has been demonstrated, and this association is not recognised by any UK medical authority. Believing this myth may cause unnecessary anxiety and distract individuals from identifying and addressing genuine, treatable causes of their hair loss. If you are concerned about hair thinning, speaking with a GP or dermatologist is always the most appropriate course of action.

Have questions about your medication? Our pharmacists are here to help →

Hormones, DHT, and Hair Loss: Separating Fact from Myth

It is genetic sensitivity of hair follicles to DHT — not testosterone levels raised by any behaviour — that drives androgenetic alopecia. Brief hormonal fluctuations from sexual activity do not alter the long-term follicular hormonal environment.

To understand why the masturbation–hair loss myth persists, it helps to understand the genuine hormonal mechanisms behind androgenetic alopecia. Dihydrotestosterone (DHT) is an androgen derived from testosterone through the action of an enzyme called 5-alpha reductase. In individuals who are genetically predisposed, DHT binds to receptors in scalp hair follicles, causing them to miniaturise progressively — a process known as follicular miniaturisation. Over time, affected follicles produce thinner, shorter hairs until they eventually cease producing hair altogether.

Critically, it is genetic sensitivity of the hair follicles to DHT — not the absolute level of testosterone or DHT in the bloodstream — that determines whether someone develops pattern hair loss. This is why some men with relatively low testosterone levels still experience significant baldness, whilst others with high testosterone retain a full head of hair throughout their lives. The myth that any activity raising testosterone (including masturbation) will accelerate hair loss fundamentally misunderstands this mechanism.

Hormonal hair loss in women is more complex and often involves conditions such as polycystic ovary syndrome (PCOS), which elevates androgen levels, or the hormonal shifts associated with menopause. In these cases, the underlying hormonal imbalance — not any behavioural factor — is the driver of hair thinning.

Where a hormonal contribution to hair loss is suspected in women, a GP may arrange targeted blood tests based on clinical presentation. These may include total testosterone, sex hormone-binding globulin (SHBG, used to calculate the free androgen index), thyroid-stimulating hormone (TSH), and prolactin, amongst others, in line with current NICE guidance on PCOS and female pattern hair loss. The specific tests requested will depend on the individual's symptoms and history.

Women presenting with features of significant hyperandrogenism — such as rapidly progressive hair loss, virilisation, or severe hirsutism — should be referred promptly to an appropriate specialist (endocrinology or dermatology) for further assessment.

In summary, whilst DHT genuinely plays a central role in androgenetic alopecia, the pathway to elevated DHT activity in follicles is determined by genetics and systemic hormonal conditions — not by sexual behaviour or frequency of masturbation.

When to Seek Medical Advice About Hair Loss

You should contact your GP if you experience sudden, patchy, or rapidly progressive hair loss, scalp inflammation, hair loss in a child, or thinning alongside systemic symptoms such as fatigue or menstrual irregularities. Early assessment improves outcomes for many treatable causes.

Some degree of hair shedding is entirely normal and part of the natural hair growth cycle. However, there are circumstances in which hair loss warrants prompt medical assessment. Recognising these triggers can help ensure that any underlying condition is identified and managed early.

Consider contacting your GP if you notice:

• Sudden or rapid hair loss over a short period

• Patchy hair loss, particularly in circular or irregular patterns

• Hair loss accompanied by scalp redness, scaling, itching, pain, or inflammation — particularly a boggy, tender plaque, which may suggest a kerion (a severe form of tinea capitis requiring urgent treatment)

• Signs of scarring on the scalp, which may indicate a scarring alopecia requiring prompt specialist referral to prevent permanent follicle loss

• Hair loss in a child, which may indicate tinea capitis and requires assessment for systemic antifungal treatment

• Hair thinning alongside other symptoms such as fatigue, weight changes, or menstrual irregularities, which may suggest a thyroid disorder, iron deficiency, or hormonal imbalance

• Hair loss following a new medication — your GP can review whether this is a known side effect

• Significant psychological distress related to hair loss, which is a valid and important reason to seek support

Your GP will typically begin with a thorough history and examination, and may arrange blood tests to exclude treatable causes such as iron deficiency anaemia, thyroid dysfunction, or other relevant conditions based on your clinical picture. In more complex cases, referral to a consultant dermatologist via the NHS is the appropriate pathway. The Primary Care Dermatology Society (PCDS) and the British Association of Dermatologists (BAD) provide guidance to support GPs in assessing and referring hair loss appropriately.

It is worth noting that early intervention often yields better outcomes, particularly for conditions such as alopecia areata or telogen effluvium, where addressing the trigger can allow significant regrowth. Do not delay seeking advice — hair loss is a medical concern like any other, and healthcare professionals are well placed to help.

Evidence-Based Treatments for Hair Loss Available in the UK

Topical minoxidil (licensed OTC for men and women) and finasteride 1 mg daily (prescription-only for men) are the main evidence-based treatments for androgenetic alopecia in the UK. Treatment choice depends on the underlying cause and should be guided by a GP or dermatologist.

For those experiencing genuine hair loss, a range of evidence-based treatments are available in the UK, depending on the underlying cause and severity. It is important to approach treatment through a healthcare professional rather than relying on unregulated supplements or products making unsubstantiated claims.

Topical minoxidil is one of the most widely used and evidence-supported treatments for androgenetic alopecia. It is available over the counter in the UK as a topical solution or foam, and is licensed for use in both men and women. Minoxidil works by prolonging the anagen (growth) phase of the hair cycle and improving blood flow to follicles. Results require consistent, long-term application and may take several months to become apparent.

Oral minoxidil is sometimes used for hair loss but is not licensed for this indication in the UK and is therefore prescribed off-label. Its use should be initiated and supervised by a specialist, with careful assessment of cardiovascular risks (including hypotension, fluid retention, and tachycardia) and potential for hypertrichosis. It is not suitable for all patients.

Finasteride 1 mg daily is an oral prescription medication licensed in the UK for male pattern baldness in men only. It works by inhibiting 5-alpha reductase, thereby reducing DHT levels in the scalp. Clinical evidence demonstrates significant slowing of hair loss and modest regrowth in many men. Finasteride is not licensed for use in women of childbearing potential due to the risk of harm to a male foetus; women who are or may become pregnant should not handle crushed or broken tablets.

Importantly, the MHRA has issued Drug Safety Updates highlighting that finasteride can cause sexual side effects (including decreased libido, erectile dysfunction, and ejaculation disorders) and psychiatric side effects (including depression and, rarely, suicidal ideation). These effects may persist after stopping treatment in some individuals. Patients should be provided with a patient alert card at the time of prescribing and encouraged to report any new symptoms to their prescriber promptly. Brand names should not be used as a guide to prescribing; refer to the current Summary of Product Characteristics (SmPC) via the electronic Medicines Compendium (eMC) and the BNF for full prescribing information.

Dutasteride is sometimes used off-label for androgenetic alopecia in men but is not licensed for this indication in the UK.

For alopecia areata, treatment options include topical, intralesional, or systemic corticosteroids depending on severity and extent. For severe alopecia areata, ritlecitinib (Litfulo) has received MHRA approval and is the JAK inhibitor currently supported for use in this indication in the UK; patients should be assessed against relevant NICE commissioning criteria. Clinicians should refer to current NICE technology appraisal guidance and the relevant SmPC for eligibility and monitoring requirements.

Telogen effluvium typically resolves once the underlying trigger — such as nutritional deficiency, significant stress, or illness — is identified and addressed.

The NHS provides access to psychological support and referral to specialist hair loss clinics where appropriate. Patients are encouraged to discuss all options with their GP or dermatologist to identify the most suitable, evidence-based approach for their individual circumstances.

If you experience a suspected side effect from any hair loss treatment, you can report it directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. This applies to both prescription and over-the-counter medicines.

Frequently Asked Questions